Transforming what is possible in neuroscience
Founded in late 2018 through a partnership with Pfizer and Bain Capital, Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.
We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of seasoned leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with expertise in clinical design and execution as well as drug discovery and development.
Our mission: push boundaries, develop solutions and transform lives.
Unraveling the mysteries of the brain
Twenty years of research and investment by Pfizer, supported by an initial capital commitment from an affiliate of Bain Capital and a keystone equity position from Pfizer, has resulted in our broad and diverse pipeline, which is comprised of preclinical and five clinical-stage therapeutic candidates directed toward the treatment of various neurological disorders, including Parkinson’s disease, epilepsy and schizophrenia.
With our unique heritage, we are powered to advance our current research and development programs while exploring new modalities through internal research efforts and external collaborations.
Our responsibility is to
serve our patients and our people
Our leadership team has a multi-decade track record of drug approvals and commercial success, and the depth and breadth of experience to enable us to create a leading neuroscience drug discovery and development platform to transform the lives of patients living with some of the most devastating neuroscience diseases.
Supported by a seasoned Board of Directors
